Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.46 |
| ▸ | CTSS | P25774 | 10/20 | 0.46 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938304 | 1.00 | CTSK (0.46) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL879326 | 1.00 | CTSK (0.46) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL1688920 | 0.92 | CTSK (0.47) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL3733285 | 0.92 | CTSK (0.47) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL3735030 | 0.92 | CTSK (0.47) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL14721778 | 0.89 | ACE (0.40) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL14721779 | 0.89 | ACE (0.40) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL15962292 | 0.89 | ACE (0.40) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL18397664 | 0.88 | CYP1A2 (0.57) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL13239937 | 0.88 | CTSK (0.43) | CTSKCTSSCTSLCTSBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019076986-A1 | 6-SUBSTITUTED 3-FLUORO-2-PYRIDINALDOXIME, 3-FLUORO-2-PYRIDINE HYDROXAMIC ACID, AND 3-FLUORO-2-PYRIDINAMIDOXIME SCAFFOLDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-04-25 | — | — | WO | disclosed |
| EP-3473618-A1 | 6-SUBSTITUTED 3-FLUORO-2-PYRIDINALDOXIME, 3-FLUORO-2-PYRIDINE HYDROXAMIC ACID, AND 3-FLUORO-2-PYRIDINAMIDOXIME SCAFFOLDS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-04-24 | — | — | EP | disclosed |
| US-8022210-B2 | 3-Aminopyrazine-2-carbonylguanidine derivatives; (4-{4-[N'-(3,5-Diamino-6-chloropyrazine-2-carbonyl)guanidino]butyl}phenoxy)acetic acid 2-piperidin-1-yl-ethyl ester; hydration of mucous membranes; respiratory system and gastrointestinal disorders; skin, eye and vaginal dryness; hypotensive agents; asthma | PARION SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-8008494-B2 | 2-(4-{4-[N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidino]-butyl}phenoxy)-N-(3-dimethylaminopropyl)acetamide dimethanesulfonate; promoting hydration of mucosal surfaces; Sjogren's disease, esophagitis, pneumonia, asthma, otitis, constipation, chronic diverticulitis, rhinosinusitis | PARION SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-7875619-B2 | N-[4-(4-{2-[bis-((2S,3R)-2,3,4-trihydroxybutyl)amino]ethylamino}phenyl)butyl]-N'-(3,5-diamino-6-chloropyrazine-2-carbonyl)guanidine trihydrochloride; treating chronic bronchitis, cystic fibrosis, ventilator-induced pneumonia, asthma, chronic obstructive pulmonary disease, pneumonia and emphysema | PARION SCIENCES, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7842697-B2 | Soluble amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090324724-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090076273-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| EP-1599096-B1 | HETERO SUBSTITUED SODIUM CHANNEL BLOCKERS | PARION SCIENCES INC (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080177072-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-6668527-B2 | Antiinflamamtory agents; autoimmune disease | PFIZER INC. | 2003-12-30 | — | — | US | disclosed |
| US-6667331-B2 | For example 3-(2-(1-(2-(3-Methoxy-4-(3-o-tolyl-ureido)-phenyl)-acetylamino )-3-methyl-butyl)-4,5-dihydro-oxazol-5-yl)-2-methyl-propionic acid | PFIZER INC | 2003-12-23 | — | — | US | disclosed |
| US-20030100585-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | DUPLANTIER ALLEN J (US) | 2003-05-29 | — | — | US | disclosed |
| US-20030004196-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | DUPLANTIER ALLEN J (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1244656-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | Pfizer Products Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| US-20020049236-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | PFIZER INC. | 2002-04-25 | — | — | US | disclosed |
| WO-2001051487-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | PFIZER PRODUCTS INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| US-5665598-A | Synthesis of chiral N-protected-α-substituted-glycine free acids by zinc-mediated addition of organic halide to glycine cation equivalent | G. D. SEARLE & CO. (US) | 1997-09-09 | — | — | US | disclosed |
| US-5508466-A | REACTING MIXTURE OF N-PROTECTED-ALPHA-SUBSTITUTED-GLYCINE CATION DERIVATIVE AND ELEMENTAL ZINC WITH ORGANIC HALIDE IN POLAR SOLVENT | G.D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004196-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, SELPLG, CCR10 | CTSK 851/4885CTSS 1285/4885CTSL 248/4885 |
| US-20020049236-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, CCR10, SELPLG | CTSK 774/4885CTSS 1590/4885CTSL 309/4885 |
| US-20090324724-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | SCN2A, CACNA1B, HCN4 | CTSK 3600/4885CTSS 3583/4885CTSL 3027/4885 |
| US-20080177072-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | SCN2A, CACNA1B, HCN4 | CTSK 3600/4885CTSS 3583/4885CTSL 3027/4885 |
| US-20090076273-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | SCN2A, CACNA1B, HCN4 | CTSK 3600/4885CTSS 3583/4885CTSL 3027/4885 |
| US-20030100585-A1 | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases | VCAM1, SELP, SELPLG | CTSK 2514/4885CTSS 2202/4885CTSL 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.